Citigroup Lowers Zoetis (NYSE:ZTS) Price Target to $96.00

Zoetis (NYSE:ZTS) had its price target decreased by investment analysts at Citigroup from $112.00 to $96.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 27.60% from the company’s current price.

Several other research analysts have also recently issued reports on the stock. Stifel Nicolaus cut their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. TD Cowen dropped their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis Trading Up 0.5%

Shares of NYSE ZTS traded up $0.41 during midday trading on Tuesday, reaching $75.23. The company had a trading volume of 3,132,580 shares, compared to its average volume of 5,799,756. Zoetis has a one year low of $71.45 and a one year high of $160.48. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm’s fifty day moving average price is $76.60 and its 200-day moving average price is $100.24. The stock has a market cap of $31.54 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 1.21 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period last year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts anticipate that Zoetis will post 6.43 earnings per share for the current year.

Insider Buying and Selling at Zoetis

In related news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZTS. Westport Asset Management Inc. purchased a new stake in Zoetis in the second quarter worth $287,000. Flossbach Von Storch SE purchased a new position in Zoetis during the second quarter valued at $302,601,000. Wealthfront Advisers LLC boosted its holdings in shares of Zoetis by 80.2% during the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after buying an additional 33,873 shares in the last quarter. Main Street Financial Solutions LLC bought a new stake in shares of Zoetis during the 2nd quarter valued at $3,819,000. Finally, First National Bank of Omaha grew its position in shares of Zoetis by 16.5% in the 2nd quarter. First National Bank of Omaha now owns 3,882 shares of the company’s stock worth $284,000 after buying an additional 551 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: BNP Paribas Exane lowered its price target to $110 from $146 but retained an “outperform” rating. The new target still implies approximately 46.5% upside, signaling that the firm views Zoetis’ recent weakness as excessive. Tickerreport article
• Neutral Sentiment: Analyst coverage remains divided. JPMorgan reportedly reduced its price target to $115, while broader commentary continues to assess whether Wall Street is bullish or bearish on Zoetis. The target remains well above the current trading level, but the cuts point to more cautious expectations. JPMorgan price target article
• Neutral Sentiment: Zoetis’ incoming finance chief is expected to take on responsibilities similar to a chief operating officer, reflecting a broader trend of companies combining CFO and COO duties. The change could improve operational oversight, although investors may initially view it as part of a broader leadership transition. Fortune leadership article
• Negative Sentiment: Piper Sandler cut its target to $80 from $90 and shifted to a “neutral” rating, leaving only about 6.5% implied upside. Analysts cited competitive pressures and leadership changes as factors shaping the outlook. Benzinga analyst update
• Negative Sentiment: Recent commentary highlights investor concerns after Zoetis’ latest quarter: earnings modestly exceeded estimates, but revenue slightly missed forecasts and declined year over year. Fiscal 2026 EPS guidance of $6.15–$6.25 is also below the roughly $6.43 analyst consensus, reinforcing worries about slower growth and competitive pressure. Yahoo Finance Zoetis Q2 deep dive

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.